Clinical trials: Syndrome, Metabolic
Menopause, Climacteric Syndrome
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
The study collected retrospective data from the assumption of combined natural molecules in menopausal women with metabolic syndrome
- Conditions
- Menopause, Climacteric Syndrome, Metabolic Syndrome
- Trial name
- NCT06057896
- Testing
- inositol, phytoestrogens, cocoa polyphenols
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lo.Li.Pharma s.r.l
Lactose Intolerance
Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects
Randomized, open-label, 2-period, 2-sequence, crossover study to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28.
- Trial name
- RP (NCT03563846)
- Testing
- RP-G28
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Ritter Pharmaceuticals, Inc.
Type 2 Diabetes, Metabolic Syndrome
Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
This is a Phase 2, open-label, single-arm study of the safety and tolerability of PBI-4050 800 mg daily oral administration in type 2 diabetes patients with metabolic syndrome.
- Trial name
- NCT02562573
- Testing
- PBI4050
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Liminal BioSciences Ltd.
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Mucopolysaccharidosis Type II, Metabolic Diseases
A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.
- Trial name
- NCT05208281
- Testing
- GNR-055 1.0-2.0-3.0 mg/kg, GNR-055 2.0 mg/kg, GNR-055 3.0 mg/kg
- Where
- 5 sites in Russia
- Volunteers
- 32 people
- Sponsor
- AO GENERIUM
Respiratory Disease, Asthma
Digital App for Telerehabilitation in Respiratory Diseases
The purpose of this study is to evaluate the feasibility and the mid-term effects of a pulmonary rehabilitation intervention, delivered by digital App, on quality of life of patients affected by respiratory diseases.
- Conditions
- Respiratory Disease, Asthma, Long COVID, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT05572346
- Testing
- Home-based telerehabilitation program delivered through digital devices
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- MedicAir Healthcare S.r.l.
Celiac Disease
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
This study is designed to evaluate the efficacy of a single dose of larazotide acetate in preventing intestinal permeability changes induced by a 6-week gluten challenge in subjects with celiac disease
- Trial name
- NCT00889473
- Testing
- Larazotide acetate, Gluten 900 mg
- Where
- 15 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- 9 Meters Biopharma, Inc.
Non-Celiac Gluten Sensitivity
Efficacy of Probiotic ES1 for the Treatment of Non-Celiac Gluten Sensitivity
Study to demonstrate the efficacy of Probiotic ES1 in alleviating symptoms of gluten sensitivity in non-celiac gluten sensitive subjects exposed to a small, fixed amount of gluten.
- Trial name
- NCT02810301
- Testing
- Probiotic ES1
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Exzell Pharma Inc.
Heart Failure, Congestive Heart Failure
Alfapump Direct Sodium Removal (DSR) Feasibility Study
First in Human feasibility and sfafety study of the alfapump DSR system in the treatment of Heart failure subects resistant to diuretic therapy.
- Conditions
- Heart Failure, Congestive Heart Failure, Cardiorenal Syndrome, Volume Overload
- Trial name
- RED DESERT (NCT04116034)
- Testing
- alfapump DSR system
- Where
- 2 sites in Belgium, Georgia
- Volunteers
- 8 people
- Sponsor
- Sequana Medical N.V.
Mucopolysaccharidosis I, Hurler Syndrome
Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease
This is a multi-center, open label, study conducted to evaluate the safety of laronidase administered by intravenous drip infusion in Japanese patients with MPS I disease.
- Conditions
- Mucopolysaccharidosis I, Hurler Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
- Trial name
- NCT00258011
- Testing
- Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- Where
- 2 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Genzyme, a Sanofi Company
Prader-Willi Syndrome
Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome
This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made chemical that is like oxytocin).
- Trial name
- CARE-PWS (NCT03649477)
- Testing
- 3.2 mg intranasal carbetocin, 9.6 mg intranasal carbetocin
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 130 people
- Sponsor
- Levo Therapeutics, Inc.
Metabolic Syndrome
Trial to Evaluate the Effect of Plantago Ovata Husk in the Remission of Metabolic Syndrome in Children and Adolescents
The metabolic syndrome represents a constellation of risk factors associated to the abdominal obesity that includes insulin resistance, lipids alterations, high blood pressure etc.
- Trial name
- NCT00748787
- Testing
- Ispaghula husk
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- Rottapharm Spain
Iron Deficiency Anemia
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
This study aims to explore the safety and preliminary efficacy of a response-guided dose titration of KER-047 in the treatment of functional IDA (Iron deficiency anemia) in MDS (Myelodysplastic syndrome), MF(Myelofibrosis), and…
- Trial name
- NCT05927012
- Testing
- KER-047
- Where
- 5 sites in Australia, Israel
- Sponsor
- Keros Therapeutics, Inc.
Celiac Disease
Safety and Efficacy of ALV003 for the Treatment of Celiac Disease
A phase 2a study to evaluate the safety and efficacy of ALV003 to treat celiac disease.
- Trial name
- NCT00959114
- Testing
- ALV003
- Where
- Finland
- Volunteers
- 74 people
- Sponsor
- Alvine Pharmaceuticals Inc.
Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD)
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum
The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with frontotemporal lobar degeneration (FTLD) syndromes.
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Corticobasal Degeneration, Corticobasal Syndrome (CBS)
- Trial name
- ReMoTe (NCT07569367)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioSensics
Hemophilia B, Mucopolysaccharidosis I
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol.
- Conditions
- Hemophilia B, Mucopolysaccharidosis I, Mucopolysaccharidosis II
- Trial name
- LTFU (NCT04628871)
- Testing
- SB-318, SB-913, SB-FIX
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Sangamo Therapeutics
Diabetes Mellitus
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes
The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with…
- Trial name
- PROactive (NCT00174993)
- Testing
- Pioglitazone
- Where
- 19 sites in Austria, Belgium and 17 more
- Volunteers
- 4,373 people
- Sponsor
- Takeda
Metabolic Syndrome X
Study In Patients With Dyslipidaemia
Study in patients with dyslipidaemia.
- Trial name
- NCT00264667
- Testing
- GW677954
- Where
- 50 sites in Argentina, Australia and 11 more
- Volunteers
- 290 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus Type 2
GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes
Obstructive Sleep Apnea (OSA) and type 2 diabetes mellitus are two prevalent medical conditions with significant associated cardiovascular and cerebrovascular morbidity and mortality.
- Trial name
- NCT00509223
- Testing
- Positive Airway Pressure therapy, Lifestyle counseling
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 416 people
- Sponsor
- ResMed
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals